Critical care medicine

JAMA

Volumn 275, Issue 23, 1996, Pages 1799-1800

  Hollenberg, Steven M ^a   Parrillo, Joseph E ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; ENDOTOXIN ANTIBODY; HYPERTENSIVE FACTOR; INOTROPIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY; VASODILATOR AGENT;

AEROBIC METABOLISM; CLINICAL TRIAL; CRITICAL ILLNESS; HEART OUTPUT; HUMAN; INTENSIVE CARE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; RESUSCITATION; SEPSIS; SEPTIC SHOCK; SHOCK; SHORT SURVEY; SURVIVAL; TREATMENT OUTCOME;

EID: 0029927247     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.23.1799     Document Type: Short Survey

References (15)

1. Shoemaker WC, Appel PL, Kram HB. Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest. 1992;102:208-215.
2. Boyd O, Grounds RM, Bennett ED. A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA. 1993;270:2699-2707.
3. Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest. 1992;102:216-220.
4. Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717-1722.
5. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med. 1996;333:1025-1032.
6. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR, CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med. 1994;121:1-5.
7. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med. 1995;23:994-1006.
8. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-941.
9. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA. 1994;271:1836-1843.
10. Suffredini AF. Current prospects for the treatment of clinical sepsis. Crit Care Med. 1994;22(suppl):12-18.
11. Oye RK, Bellamy PE. Patterns of resource consumption in medical intensive care. Chest. 1991;99:685-689.
12. Knaus WA, Harrell FE Jr, Lynn J, et al. The SUPPORT prognostic model: objective estimates of survival for seriously ill hospitalized adults. Ann. Intern Med. 1995;122:191-203.
13. Esserman L, Belkora J, Lenert L. Potentially ineffective care: a new outcome to assess the limist of critical care. JAMA 1995;274:1544-1551.
14. SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients: the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). JAWA. 1995;274:1591-1598. Correction: JAMA. 1996;275:1232.
15. Civetta JM, Hudson-Civetta JA, Nelson LD. Evaluation of APACHE II for cost containment and quality assurance. Ann Surg. 1990;212:266-274.